Advancing atherosclerosis treatment: Drug encapsulation nanosystems and synthetic HDL nanoparticles

Abstract

Atherosclerosis, characterized by plaque accumulation in arterial walls, remains a leading cause of cardiovascular disease. Current pharmacological treatments often lack efficacy in halting disease progression or addressing systemic complications. Nanotechnology offers promising solutions, including targeted drug delivery, enhanced bioavailability, and the ability to overcome biological barriers. This review explores the integration of drug-delivery nanosystems and synthetic high-density lipoprotein (HDL) nanoparticles into therapeutic strategies. Synthetic HDL nanoparticles not only serve as effective carriers for antidyslipidemic drugs but also act directly as functional HDL, improving lipid profiles and reducing systemic side effects. By enabling localized treatment and enhancing therapeutic precision, nanotechnology and synthetic HDL nanoparticles represent a paradigm shift in managing atherosclerosis, offering safer and more effective alternatives for preventing its life-threatening complications.

Keywords: atherosclerosis; drug delivery systems; dyslipidemia; nanotechnology; synthetic HDL nanoparticles.